Meningococcal surrogates of protection--serum bactericidal antibody activity.
about
Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesImmunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccineCharacteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in UgandaImmunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.Antibody-mediated immunity to the obligate intracellular bacterial pathogen Coxiella burnetii is Fc receptor- and complement-independent.Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiencyTiming of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagersEvaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine.Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixedFold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsPersisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccineSterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa.Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteinsComplement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.Meningococcal conjugate vaccines: optimizing global impact.Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.Development of a serological assay to predict antibody bactericidal activity against non-typeable Haemophilus influenzaeSeroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp.Some extensions in continuous models for immunological correlates of protection.The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvantFunctional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.Nomenclature for immune correlates of protection after vaccination.Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction
P2860
Q26796420-23CADA3F-AD9A-4A54-BD45-9E42A8D53806Q28749695-B768C1F7-B684-4BFB-90B2-C16934DB5775Q30248749-A60D35F9-CFB0-4138-93E2-73333BEF67FEQ33334377-D2412E41-5A1D-4BA3-9B2B-8529CAE9D72DQ33388680-C5DACDDD-3227-403B-A1F2-7EE291CB4990Q33397450-52CD77D5-4E24-4B9F-A6D4-243B668772B8Q33441877-27624B68-7EB5-42EB-B562-6CCF05177525Q33597158-150805D2-8FB2-41A8-BF29-5D6403C22147Q33609246-19681BA2-EF02-4278-BA69-4350DAB5ED42Q33768741-FF454D2E-D659-477A-8A8F-27EA2EC4BF97Q33806774-3A4E5012-A2E6-45A8-B120-2A0E73200FFEQ33895627-42F70F40-A24D-4045-B52F-42E3C006AFF7Q33939014-839DE5C2-9BD8-4A79-9910-330C16FD5242Q33962704-2C739487-72E9-431F-AB3E-7A7F039179CEQ34155231-C3A4DB09-EE66-4FD0-8CE9-B51930FE57E7Q34194667-DD526762-3FB4-4057-B683-BDB8AD7A130DQ34430200-038DF174-6FD9-41FA-A707-5F44564B5F92Q34627685-4F892063-B6BA-4759-B82D-0547953442FDQ34694957-802E55DB-77F1-4879-BB14-FC8BDB5AFA45Q34720380-AC42690B-072E-47BC-A4A9-D7FA4E414311Q34889968-007927B3-F3F0-4BA1-8990-DDFE98427601Q34916705-C2211A39-67FC-4510-B291-63A47AA46707Q35075181-15E9882A-018E-46F1-A13D-83AA8F19272AQ35191862-8A604C2A-9C55-49C7-9D7B-D3F446B15C73Q35217627-24FC53A9-2DB6-487B-9DD6-6D836634A339Q35547767-BD385518-A2F9-4EA6-8D87-DFC50CFEECE4Q35598188-2663623E-F5E6-405F-A237-BD01121F3A58Q35619047-ECA902EF-B988-4551-97D4-B9CF03B65A2DQ35739057-18D4CAEA-13A6-4BA7-ABAE-021B6F012D72Q35799561-18B8612C-8D20-4704-AA28-A74020082BFDQ35805284-5A6FFE84-EE9C-4D32-BF71-D657F6D7C850Q35857593-40FD96DD-59F1-4AD7-AF9F-3E07969D21AAQ35878996-70594C8C-59B6-48B2-8BC2-0EBF490012AFQ35886792-C944BBF7-8E97-4E2B-BCA2-A45D11BD6040Q35887288-C21C0518-155D-4ED9-99B0-4A56E2ED18A0Q35887397-C6E57DB9-D89E-4828-9889-51A4BF38B649Q35946901-F1271AE2-5CF1-4802-92B1-201E89CEA7F0Q35948780-DB7CB46E-009C-4E64-AFE9-C0FB8CD63D0BQ36095135-B13948E5-4F1F-427B-B9D4-3902E0FDE937Q36154716-23F1974D-9B21-4951-8D88-1A656931A165
P2860
Meningococcal surrogates of protection--serum bactericidal antibody activity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@ast
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@en
type
label
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@ast
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@en
prefLabel
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@ast
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@en
P1433
P1476
Meningococcal surrogates of protection--serum bactericidal antibody activity.
@en
P2093
Elizabeth Miller
Paul Balmer
P304
P356
10.1016/J.VACCINE.2005.01.051
P407
P50
P577
2005-03-01T00:00:00Z